A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved ...
Ever notice that as you get older, some foods no longer sit with you the same? This could be due to a breakdown of the ...
BioInvent International (STO:BINV) 46% objective response rate (6 of 13 evaluable patients) and a 92% disease control rate ...
Background Chronic hepatitis B virus (HBV) infection disproportionately affects people living with HIV, who are often excluded from functional cure studies. Objective This study investigates CD8+ T ...
Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality worldwide.1 Despite therapeutic ...
Selinexor-based regimens enhance T-cell activation in RRMM patients, without increasing inhibitory checkpoint molecules, indicating resistance is not due to T-cell exhaustion. Baseline protein ...
This valuable work investigates the role of protein N-glycosylation in regulating T-cell activation and function and suggests that B4GALT1 is a potential target for tumor immunotherapy. The strength ...
T-cell engagers, especially BiTEs, show promise in treating solid tumors by targeting tumor-associated antigens and redirecting T-cell activity. Tarlatamab, targeting DLL3 in SCLC, demonstrated ...
Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of ...
Meet the Jekyll and Hyde of the immune system: activated CD8⁺ T cells. On June 24 in Nature Immunology, researchers led by Dorian McGavern at the National Institutes of Health introduce a granzyme ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback